Scinai Completes Recipharm Israel Acquisition, Expands CDMO Platform to Two Sites
- Scinai acquired Recipharm Israel's Yavne facility, adding a second manufacturing site and $3.6 million in equipment to complement its Jerusalem biologics operation.
- The combined CDMO platform now offers biologics, sterile injectables, and small-molecule API development and manufacturing across two Israeli locations.
- Q1 2026 CDMO revenues included ~$200K from the newly acquired Yavne facility; Scinai entered a strategic commercial collaboration with global CDMO leader Recipharm AB.
Operational Impact
Scinai's acquisition of Recipharm Israel's Yavne facility expands its CDMO service portfolio from biologics-only to include sterile injectables and small-molecule APIs, broadening the addressable customer base and manufacturing footprint across two Israeli sites.
Source: PR Newswire pharma category RSS